Search Results Search Sort by RelevanceMost Recent Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004; 6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004; 6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004; 6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408. Medicine and Society Oct 2004 Television on the Cutting Edge: Cosmetic Surgery Goes Prime-Time Leigh Turner, PhD Reality television programs that focus on cosmetic surgery show misguided viewers that such procedures are the key to emotional health and well-being. Virtual Mentor. 2004; 6(10):462-464. doi: 10.1001/virtualmentor.2004.6.10.msoc1-0410. Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024; 26(7):E562-571. doi: 10.1001/amajethics.2024.562. Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024; 26(7):E551-561. doi: 10.1001/amajethics.2024.551. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024; 26(7):E512-519. doi: 10.1001/amajethics.2024.512. Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024; 26(7):E587-590. doi: 10.1001/amajethics.2024.587. History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024; 26(7):E580-586. doi: 10.1001/amajethics.2024.580. Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024; 26(7):E527-533. doi: 10.1001/amajethics.2024.527. Pagination First page « First Previous page ‹ Previous … Page 24 Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Page 32 Next page Next › Last page Last »
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004; 6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004; 6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004; 6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408.
Medicine and Society Oct 2004 Television on the Cutting Edge: Cosmetic Surgery Goes Prime-Time Leigh Turner, PhD Reality television programs that focus on cosmetic surgery show misguided viewers that such procedures are the key to emotional health and well-being. Virtual Mentor. 2004; 6(10):462-464. doi: 10.1001/virtualmentor.2004.6.10.msoc1-0410.
Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024; 26(7):E562-571. doi: 10.1001/amajethics.2024.562.
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024; 26(7):E551-561. doi: 10.1001/amajethics.2024.551.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024; 26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024; 26(7):E587-590. doi: 10.1001/amajethics.2024.587.
History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024; 26(7):E580-586. doi: 10.1001/amajethics.2024.580.
Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024; 26(7):E527-533. doi: 10.1001/amajethics.2024.527.